World Cancer Research Fund UK

Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy

Retrieved on: 
Monday, June 12, 2023
Medical Devices, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, DNA, Drug development, Therapy, World Cancer Research Fund UK, Cognate, Cancer, Bladder cancer, Transfection, Food and Drug Administration Amendments Act of 2007, CDMO, Investigational New Drug, Patient, RNA interference, CRL, FDA, IND, NYSE, Food, Pharmaceutical industry, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Curigin , a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, today announced a collaboration for adenoviral vector production.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Curigin , a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, today announced a collaboration for adenoviral vector production.
  • The gene therapy developer will leverage Charles River's market-leading expertise in contract development and manufacturing organization (CDMO) solutions to support its preclinical and clinical trials.
  • Curigin develops anticancer gene therapy products that utilize innovative genetically engineered viruses and novel RNAi technology to quickly and accurately block key disease-specific genetic signal pathways, effectively switching off genes responsible for tumor growth.
  • Expanding its comprehensive cell and gene therapy portfolio to span viral vector, plasmid DNA, and cell therapy production, through the acquisitions of Vigene Biosciences, Cobra Biologics, and Cognate BioServices in 2021, Charles River offers end-to-end support and supply chain simplification for gene therapy developers.

Cytovia Therapeutics Presents New Data on CD38-Targeted Flex-NK™ Bispecific Antibody at 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Friday, December 9, 2022
Lynx, Laboratory, Therapy, Ink, Multiple myeloma, National Cancer Institute, INSERM, Society, Cancer, Macrophage, Deep learning, CAR, Lymphatic system, Cornerstone, Natural killer T cell, BCMA, Standard of care, American Society of Hematology, Poster, Partnership, TALEN, Cell, Bone marrow, Multimedia, B cell, Immunotherapy, Transplant, Cellectis, Daratumumab, NK, Glioblastoma, Whole blood, CD38, Monoclonal antibody, Microfluidics, World Cancer Research Fund UK, ASH, Hematology, Protein, Patient, Research, UCSF, Survival, Death, Safety, HCC, CDC, Neoplasm, Vaccine, Pharmaceutical industry, ADCP, NCR1

"We're delighted to see further progress on our CD38-targeted Flex-NK bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023," commented Cytovia CEO Dr.Daniel Teper.

Key Points: 
  • "We're delighted to see further progress on our CD38-targeted Flex-NK bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023," commented Cytovia CEO Dr.Daniel Teper.
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II
    The poster is available online on both the Cytovia Therapeutics and American Society of Hematology websites.
  • Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK bispecific antibody platforms.
  • Cytovia has developed a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities inGreater Chinaand beyond.

Cytovia Therapeutics To Present New Data on CD38 Flex-NK™ Cell Engager Bispecific Antibodies for Multiple Myeloma at 2022 ASH Annual Meeting

Retrieved on: 
Thursday, October 27, 2022
UCSF, Protein, Hepatocellular carcinoma, HCC, Bone marrow, Hematology, Ink, Natural killer T cell, American Society of Hematology, INSERM, Glioblastoma, Lymphatic system, Immunotherapy, CTCL, Cornerstone, Technology, Therapy, Patient, TALEN, Skin, National Cancer Institute, Partnership, CAR, CD38, BCMA, Research, NK, Society, Multiple myeloma, Multimedia, ASH, Cellectis, Cancer, National, B cell, Daratumumab, Transplant, Survival, Laboratory, Death, Standard of care, World Cancer Research Fund UK, Safety, Vaccine, NCR1

Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II

Key Points: 
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II
    Multiple Myeloma is a currently incurable cancer, affecting a type of white blood cell known as plasma cells.
  • It leads to an accumulation of tumor cells in the bone marrow, rapidly outnumbering healthy blood cells.
  • Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.
  • Cytovia has developed a strategic partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities inGreater Chinaand beyond.

Global Monoclonal Antibodies Market Report 2022: Cost-effective Advanced Technology for Developing mABs Presents Billion-Dollar Opportunity - ResearchAndMarkets.com

Retrieved on: 
Friday, August 26, 2022
Pharmaceutical, Health, Oncology, Lung cancer, COVID-19, Regeneron Pharmaceuticals, EUA, Conditional sentence, Breast cancer, Technology, Inflammation, Cancer, Degenerative disease, Man, Neutralizing antibody, Infection, Genetic engineering, American Institute for Cancer Research, Hospital, American Institute, Antibody, Prevalence, World Cancer Research Fund UK, CAGR, FDA, Casirivimab/imdevimab, Prostate cancer, Woman, Adoption, Employment, Patient, Vaccine

The "Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source, Production Method, Indication, Application, and End-User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source, Production Method, Indication, Application, and End-User" report has been added to ResearchAndMarkets.com's offering.
  • The monoclonal antibodies market is segmented on the basis of source, production method, indication application, and end-user.
  • By indication, the monoclonal antibodies market is segmented into cancer, autoimmune diseases, inflammatory diseases, infectious disease, microbial disease, and others.
  • The hospital segment holds the largest market share owing to the increasing adoption mABs as a preferred line of treatment against cancer.

New Study Finds AICR/WCRF’s Cancer Prevention Recommendations Are Associated With Reduced Mortality Risk From All Causes, Cancer, And Heart Disease

Retrieved on: 
Tuesday, July 5, 2022
Smoking, Death, World Cancer Research Fund UK, Cancer, Sex, NCI, Research, University, CVD, Vegetable, Meat, Current Developments in Nutrition, GLOBE, American Institute for Cancer Research, Risk assessment, Population, Center, Human, Smoker, Score, Mortality, AICR, WCRF, Risk, National Cancer Institute, Diet, Male, Survival, National, Korea Disease Control and Prevention Agency, American Institute, CDC, Hospital, Dietary supplement

They found that following a lifestyle aligned with the 2018 WCRF/AICR Cancer Prevention Recommendations was associated with a significant reduction in risk of all-cause, cancer-specific and cardiovascular-specific mortality.

Key Points: 
  • They found that following a lifestyle aligned with the 2018 WCRF/AICR Cancer Prevention Recommendations was associated with a significant reduction in risk of all-cause, cancer-specific and cardiovascular-specific mortality.
  • This study found that each one-point increase in the 2018 WCRF/AICR Score was associated with a 9-26% reduced mortality risk, except in current male smokers cancer mortality risk; the strongest associations were seen in former smokers.
  • These results underline the importance of following the AICRs 10 Cancer Prevention Recommendations to reduce cancer risk and mortality.
  • Find evidence-based tools and information for lowering cancer risk, including AICRs Cancer Prevention Recommendations, at aicr.org .

EdiGene Enters Research Collaboration With Peking University Cancer Hospital to Advance the Development of Targeted Therapy for Colorectal Cancer

Retrieved on: 
Wednesday, April 13, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, CEO, Colorectal cancer, World Cancer Research Fund International, Research, WCRF, RNA, Department, Patient, Biomarker, Gene editing, World, Lists of diseases, World Cancer Research Fund UK, IARC, Stem cell, Gene, Large intestine, Mutation, Lung cancer, Precision medicine, Pharmaceutical industry, Medical imaging, Cancer

The research result is expected to enable the development of precision medicine for patients pre-screened by specific mutation patterns.

Key Points: 
  • The research result is expected to enable the development of precision medicine for patients pre-screened by specific mutation patterns.
  • By leveraging EdiGenes systematic research on related genes responding to specific targeted therapy for advanced colorectal cancer, and our extensive research and practical experience, we will support the development of innovative therapies for patients with advanced colorectal cancer.
  • EdiGenes high-throughput genome-editing screening platform uses high-throughput screening and bioinformatics analysis to develop new biomarkers and potential targeted therapies.
  • This collaboration will explore biomarkers that are applicable to patients in China with advanced colorectal cancer to identify targeted therapies best suited to treat their particular cancer.

Global Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 23, 2022
Infectious Diseases, Biotechnology, Health, Oncology, Prostate cancer, Conditional sentence, Employment, Degenerative disease, Growth, Hospital, Time, Genetic engineering, Prevalence, Man, COVID-19, Industry, Infection, Breast cancer, Antibody, Regeneron Pharmaceuticals, American Institute, Adoption, Woman, Inflammation, American Institute for Cancer Research, EUA, FDA, Lung cancer, Cancer, Patient, Technology, CAGR, Neutralizing antibody, Casirivimab/imdevimab, World Cancer Research Fund UK, Vaccine, Fine chemical, Marketing

The "Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source, Production Method, Indication, Application, and End-User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source, Production Method, Indication, Application, and End-User" report has been added to ResearchAndMarkets.com's offering.
  • The monoclonal antibodies market is segmented on the basis of source, production method, indication application, and end-user.
  • By indication, the monoclonal antibodies market is segmented into cancer, autoimmune diseases, inflammatory diseases, infectious disease, microbial disease, and others.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Nylabone Donates Portion of Pink Dog Chew Toy Sales to National Breast Cancer Foundation, Inc.

Retrieved on: 
Monday, October 4, 2021
Veterinary, Women, Pets, Specialty, Philanthropy, Consumer, Health, Foundation, Retail, Oncology, World Cancer Research Fund UK, Partnership, Friends, Woman, Parent, Charity, NASDAQ, Cancer, Multimedia, Boredom, Central Gardens, Memphis, National Breast Cancer Foundation, CEO, Dog, Awareness, Human, History, Organic, Organization, Veterinarian, Breast cancer, PETS, Education, Birth control, Nylabone, Central Garden & Pet, National Breast Cancer Foundation, Inc., NYLABONE, CENTRAL GARDEN & PET, NATIONAL BREAST CANCER FOUNDATION, INC.

The extra-large Power Chew toy is designed in a special-edition shade of pink, the universal color for breast cancer awareness.

Key Points: 
  • The extra-large Power Chew toy is designed in a special-edition shade of pink, the universal color for breast cancer awareness.
  • According to the World Cancer Research Fund , breast cancer is the most common cancer in women worldwide.
  • The USA-made pink chew toy comes in Nylabones iconic Souper shape and is made of the brands toughest material.
  • Recognized as one of the leading breast cancer organizations in the world, National Breast Cancer Foundation (NBCF) is Helping Women Now by providing early detection, education, and support services to those affected by breast cancer.

Landmark Cancer Prevention Report Shows Consensus Among Global Experts On 10 Steps To Reduce Risk

Retrieved on: 
Wednesday, May 23, 2018
Health, American Institute for Cancer Research, Cancer research, Medicine, Cancer, Cancer prevention, Preventive healthcare, AICR, Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective, World Cancer Research Fund UK

Independent experts from across the globe reviewed decades of scientific evidence to develop the most reliable cancer prevention advice currently available, summarized in 10 cancer prevention recommendations.

Key Points: 
  • Independent experts from across the globe reviewed decades of scientific evidence to develop the most reliable cancer prevention advice currently available, summarized in 10 cancer prevention recommendations.
  • The Third Expert Report, Diet, Nutrition, Physical Activity, and Cancer: A Global Perspective ,released by the American Institute for Cancer Research (AICR) and the World Cancer Research Fund presents evidence-based recommendations established from rigorous analysis of the science.
  • AICR today launched Cancer Health Check an easy-to-use tool, which shows how your lifestyle stacks up against known cancer risks and outlines the changes you can make to follow AICR's evidence-based Cancer Prevention Recommendations.
  • Find evidence-based tools and information for lowering cancer risk, including AICR's Recommendation for Cancer Prevention, at www.aicr.org .